Moderna Other revenue — Total Revenue decreased by 51.9% to $37.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 68.2%, from $22.00M to $37.00M. Over 4 years (FY 2021 to FY 2025), Other revenue — Total Revenue shows a downward trend with a -35.7% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests successful diversification or monetization of secondary assets, while a decrease may indicate a narrowing focus on core commercial products.
This represents the total gross revenue generated from secondary business activities or non-core product lines within th...
Peers in the biotech sector often report similar non-core revenue from government grants or early-stage research collaborations.
mrna_segment_other_revenue_total_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $199.00M | $199.00M | $199.00M | $141.00M | $218.00M | $244.00M | $225.00M | $34.00M | $51.00M | $74.00M | $18.00M | $0.00 | $30.00M | $0.00 | $127.00M | $22.00M | $17.00M | $20.00M | $77.00M | $37.00M |
| QoQ Change | — | +0.0% | +0.0% | -29.1% | +54.6% | +11.9% | -7.8% | -84.9% | +50.0% | +45.1% | -75.7% | -100.0% | — | -100.0% | — | -82.7% | -22.7% | +17.6% | +285.0% | -51.9% |
| YoY Change | — | — | — | — | +9.5% | +22.6% | +13.1% | -75.9% | -76.6% | -69.7% | -92.0% | -100.0% | -41.2% | -100.0% | +605.6% | — | -43.3% | — | -39.4% | +68.2% |